........but who would want the heavy infrastructure plus all that capitalised intangible? |
& hence why they're being snapped up one by one.
Eli Lilly market cap 770Bn.
GSK 50Bn
GSK is not too big to be bid for. |
Not many interested in UK stocks right now due to the time of the year / US sucking in all the cash.
Got to think that at some point the US unwinds a little and then can we get some fresh money / buyers??
Good luck all 👍🏻 |
8x P/E 2025
7x P/E 2026
Like so, so many UK stocks should be trading at a 50% premium. |
new ceo-new strategy and primary move to US. |
How come gsk get so much good news all the time at the moment and the share price is still so subdued? What on earth will it take for market sentiment to change? |
Because it is a British company and we need as many as possible to stay on the FTSE or you may whinge a little bit more when your taxes have to go up. |
Where in the world is GSK's most important revenue raising market - would that be the UK ?, No ?
Then why is it headquartered and listed here, for old times sake ?
Time for GSK to bunk off to pastures new ? |
 GSK plc (LSE/NYSE: GSK), a global biopharmaceutical company, announced today that the European Medicines Agency (EMA) has granted its investigational drug, GSK'227, the Priority Medicines (PRIME) designation for the treatment of relapsed extensive-stage small-cell lung cancer (ES-SCLC). This regulatory acknowledgment is based on early clinical data suggesting potential therapeutic benefits in a disease marked by limited treatment options and poor patient outcomes.
The PRIME designation is designed to expedite the development and review of drugs targeting unmet medical needs. GSK'227, an antibody-drug conjugate (ADC) targeting B7-H3, has shown promise in preliminary trials. It is the second major regulatory milestone for GSK'227, following the Breakthrough Therapy Designation it received from the US Food and Drug Administration in August 2024.
Senior Vice President of Global Head Oncology at GSK, Hesham Abdullah, remarked on the significance of this development, noting the potential of GSK'227 to improve treatment for ES-SCLC and other tumor types with limited therapeutic options. The PRIME designation was supported by data from the ARTEMIS-001 study, an ongoing phase I trial conducted by Hansoh Pharma, which assessed the drug's safety and efficacy in over 200 patients with various advanced solid tumors.
Lung cancer remains one of the leading causes of cancer-related deaths globally. In Europe alone, lung cancer accounted for an estimated 484,554 new cases and 375,784 deaths in 2022. ES-SCLC, a particularly aggressive form of lung cancer, often presents with widespread disease at diagnosis and has a high rate of relapse after initial treatment. |
More tax, more wasted, more then needed as growth craters further.Most inept government in history |
Good time to invest in large uk headquartered multi national companies.Gsk is a great buy. |
Confidence in the UK markets is so low that nobody wants to invest here.
And now there is talk of an emergency tax raising budget in the spring.
God help us.
Suet |
And back below 1300 we go |
No Santa rally here lol ? |
https://fortune.com/europe/2024/12/16/gsk-silicon-valley-veteran-shobie-ramakrishnan-pharma-giant-tech-powerhouse/ |
Unfortunately Emma does not seem to inspire IIs in the same way as Mr Soirot at AZN or the turnaround bloke at RR, despite the good news of late. The CEO's profile and vision are important for a formerly significant UK Pls such as GSK. Her public profile and engagement are too low key imo. |
A red wash day all over, FED/BOE rate decisions pending Wednesday/Thursday this week weighing heavy until those are out of the way.. |
Post 33826...same VOD...should I say Lloy also... |
Spacecake that is most of the UK mkt and that's why we own almost nothing. Everything sold off on the cheap |
I have no idea why I bought this, continue to hold since 2007, even after the Haleon split there seems little direction. |
Hesham Abdullah, Senior Vice President, Global Head Oncology,R&D,GSK is a busy man signing off on RNS 's covering 3 different products within a week. |
I've been steadily increasing my position here based on that theory. Nevertheless frustrating when bad news sends shares plummeting but good news doesn't result in any uplift. At some point there will be a reversal, due to M&A activity or whatever. In the meantime we just have to grin and bear it. |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
